leokitten
Senior Member (Voting Rights)
I also just thought of a potential connection to these research results and why rituximab works in an ME subgroup.
mTOR activity also regulates immune responses and microenvironment in addition to cell cycle and metabolism. Increased mTOR activity will activate B cells via IL-2 (as well as other immune cell types).
So, given that these results show mTOR is chronically hyperactivated in ME lymphocytes, then maybe in some ME patients mTOR -> IL-2 -> B cell activation is an important driver of symptoms and killing B cells with rituximab works.
mTOR activity also regulates immune responses and microenvironment in addition to cell cycle and metabolism. Increased mTOR activity will activate B cells via IL-2 (as well as other immune cell types).
So, given that these results show mTOR is chronically hyperactivated in ME lymphocytes, then maybe in some ME patients mTOR -> IL-2 -> B cell activation is an important driver of symptoms and killing B cells with rituximab works.
Last edited: